SJP 0125

Drug Profile

SJP 0125

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Senju Pharmaceutical
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 16 Sep 2017 Phase-III clinical trials in Ocular hypertension in Japan (Ophthalmic)
  • 16 Sep 2017 Phase-III clinical trials in Open angle glaucoma in Japan (Ophthalmic)
  • 31 Jul 2017 Senju Pharmaceutical and the University of Tokyo plan a phase III trial for Open angle glaucoma and Ocular hypertension in Japan (UMIN000028494)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top